CL2013003433A1 - Método para analizar una muestra biológica de un sujeto con cáncer que comprende determinar un nivel de expresión de los biomarcadores gli-1, otx-2, shroom2, pdlim3, y sphk1 en dicha muestra, en donde el nivel de expresión de los biomarcadores en coparación con un control, proporciona un indicador de diagnóstico de si el sujeto tiene una probabilidad aumentada de respuesta a: un ácido metil-4’-trifluorometoxi-bifenil-3-carboxílixo [6-(cis-2,6-dimetil-morfolino-4-il)-piridin-3-il]-amida, ó 2-[(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2’] bipirizanil-5’-il]-propan-2-ol; método para seleccionar a un sujeto que tiene cáncer para el tratamiento con uno de dichos compuestos, el cual comprende determinar el nivel de expresión de shroom2 o sphk1, en una muestra biológica del sujeto. - Google Patents
Método para analizar una muestra biológica de un sujeto con cáncer que comprende determinar un nivel de expresión de los biomarcadores gli-1, otx-2, shroom2, pdlim3, y sphk1 en dicha muestra, en donde el nivel de expresión de los biomarcadores en coparación con un control, proporciona un indicador de diagnóstico de si el sujeto tiene una probabilidad aumentada de respuesta a: un ácido metil-4’-trifluorometoxi-bifenil-3-carboxílixo [6-(cis-2,6-dimetil-morfolino-4-il)-piridin-3-il]-amida, ó 2-[(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2’] bipirizanil-5’-il]-propan-2-ol; método para seleccionar a un sujeto que tiene cáncer para el tratamiento con uno de dichos compuestos, el cual comprende determinar el nivel de expresión de shroom2 o sphk1, en una muestra biológica del sujeto.Info
- Publication number
- CL2013003433A1 CL2013003433A1 CL2013003433A CL2013003433A CL2013003433A1 CL 2013003433 A1 CL2013003433 A1 CL 2013003433A1 CL 2013003433 A CL2013003433 A CL 2013003433A CL 2013003433 A CL2013003433 A CL 2013003433A CL 2013003433 A1 CL2013003433 A1 CL 2013003433A1
- Authority
- CL
- Chile
- Prior art keywords
- subject
- expression
- level
- shroom2
- sphk1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492603P | 2011-06-02 | 2011-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013003433A1 true CL2013003433A1 (es) | 2014-07-18 |
Family
ID=46551843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003433A CL2013003433A1 (es) | 2011-06-02 | 2013-11-29 | Método para analizar una muestra biológica de un sujeto con cáncer que comprende determinar un nivel de expresión de los biomarcadores gli-1, otx-2, shroom2, pdlim3, y sphk1 en dicha muestra, en donde el nivel de expresión de los biomarcadores en coparación con un control, proporciona un indicador de diagnóstico de si el sujeto tiene una probabilidad aumentada de respuesta a: un ácido metil-4’-trifluorometoxi-bifenil-3-carboxílixo [6-(cis-2,6-dimetil-morfolino-4-il)-piridin-3-il]-amida, ó 2-[(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2’] bipirizanil-5’-il]-propan-2-ol; método para seleccionar a un sujeto que tiene cáncer para el tratamiento con uno de dichos compuestos, el cual comprende determinar el nivel de expresión de shroom2 o sphk1, en una muestra biológica del sujeto. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20140094461A1 (es) |
EP (1) | EP2715366B1 (es) |
JP (2) | JP2014516549A (es) |
KR (1) | KR20140026537A (es) |
CN (2) | CN104975099A (es) |
AU (2) | AU2012262961A1 (es) |
BR (1) | BR112013030606A2 (es) |
CA (1) | CA2837852A1 (es) |
CL (1) | CL2013003433A1 (es) |
IL (1) | IL229336A (es) |
MA (1) | MA35395B1 (es) |
MX (1) | MX349011B (es) |
RU (1) | RU2602185C2 (es) |
SG (1) | SG194800A1 (es) |
TN (1) | TN2013000464A1 (es) |
WO (1) | WO2012166241A1 (es) |
ZA (1) | ZA201308317B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
WO2017165663A1 (en) * | 2016-03-23 | 2017-09-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Biomarkers for cancer associated with hedgehog pathway activity and related uses thereof |
CN109890390A (zh) * | 2016-11-04 | 2019-06-14 | 上海瑛派药业有限公司 | Hedgehog通路抑制剂在治疗纤维化疾病中的应用 |
WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
CN108872599A (zh) * | 2018-07-09 | 2018-11-23 | 清紫生物科技(深圳)有限公司 | PDLIM3(PDZ and LIM domain 3)用作胃癌标志物的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US20040060568A1 (en) * | 2000-10-13 | 2004-04-01 | Henryk Dudek | Hedgehog antagonists, methods and uses related thereto |
US7708998B2 (en) * | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
WO2006031977A2 (en) * | 2004-09-13 | 2006-03-23 | The Regents Of The University Of California | Inhibition of pancreatic cancer cell growth |
US20070281040A1 (en) * | 2004-09-30 | 2007-12-06 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
AU2006337085B2 (en) * | 2005-12-27 | 2013-12-19 | Curis, Inc. | Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders |
UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
BRPI0716944A2 (pt) * | 2006-09-19 | 2013-09-17 | Novartis Ag | biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf |
KR101217316B1 (ko) * | 2007-06-07 | 2012-12-31 | 아이알엠 엘엘씨 | 헷지호그 경로 조절제로서의 바이페닐카르복스아미드 유도체 |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
AR077490A1 (es) * | 2009-07-21 | 2011-08-31 | Novartis Ag | Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel |
JP5858785B2 (ja) * | 2009-07-29 | 2016-02-10 | シスメックス株式会社 | ヒトil−17産生ヘルパーt細胞検出用マーカーおよび試薬、並びにヒトil−17産生ヘルパーt細胞の検出方法 |
MX2012005695A (es) * | 2009-11-18 | 2012-06-13 | Novartis Ag | Metodos y composiciones para el tratamiento de tumores solidos y otras malignidades. |
-
2012
- 2012-04-03 US US14/122,264 patent/US20140094461A1/en not_active Abandoned
- 2012-04-03 WO PCT/US2012/031993 patent/WO2012166241A1/en active Application Filing
- 2012-04-03 MX MX2013014153A patent/MX349011B/es active IP Right Grant
- 2012-04-03 BR BR112013030606A patent/BR112013030606A2/pt not_active IP Right Cessation
- 2012-04-03 RU RU2013158650/15A patent/RU2602185C2/ru not_active IP Right Cessation
- 2012-04-03 AU AU2012262961A patent/AU2012262961A1/en not_active Abandoned
- 2012-04-03 CA CA2837852A patent/CA2837852A1/en not_active Abandoned
- 2012-04-03 CN CN201510422698.0A patent/CN104975099A/zh active Pending
- 2012-04-03 KR KR1020137031439A patent/KR20140026537A/ko not_active Application Discontinuation
- 2012-04-03 CN CN201280026951.5A patent/CN103608683A/zh active Pending
- 2012-04-03 JP JP2014513505A patent/JP2014516549A/ja not_active Withdrawn
- 2012-04-03 SG SG2013081989A patent/SG194800A1/en unknown
- 2012-04-03 EP EP12738256.2A patent/EP2715366B1/en not_active Not-in-force
-
2013
- 2013-11-06 ZA ZA2013/08317A patent/ZA201308317B/en unknown
- 2013-11-07 IL IL229336A patent/IL229336A/en not_active IP Right Cessation
- 2013-11-07 TN TNP2013000464A patent/TN2013000464A1/fr unknown
- 2013-11-29 CL CL2013003433A patent/CL2013003433A1/es unknown
- 2013-11-29 MA MA36508A patent/MA35395B1/fr unknown
-
2016
- 2016-01-20 AU AU2016200310A patent/AU2016200310A1/en not_active Abandoned
-
2017
- 2017-01-18 JP JP2017006467A patent/JP2017099394A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2012262961A1 (en) | 2013-11-28 |
JP2014516549A (ja) | 2014-07-17 |
JP2017099394A (ja) | 2017-06-08 |
MA35395B1 (fr) | 2014-09-01 |
RU2602185C2 (ru) | 2016-11-10 |
TN2013000464A1 (en) | 2015-03-30 |
CA2837852A1 (en) | 2012-12-06 |
CN103608683A (zh) | 2014-02-26 |
SG194800A1 (en) | 2013-12-30 |
WO2012166241A1 (en) | 2012-12-06 |
KR20140026537A (ko) | 2014-03-05 |
MX349011B (es) | 2017-07-05 |
NZ617421A (en) | 2016-04-29 |
EP2715366A1 (en) | 2014-04-09 |
IL229336A0 (en) | 2014-01-30 |
US20140094461A1 (en) | 2014-04-03 |
IL229336A (en) | 2017-02-28 |
BR112013030606A2 (pt) | 2016-12-13 |
ZA201308317B (en) | 2014-07-30 |
AU2016200310A1 (en) | 2016-02-11 |
EP2715366B1 (en) | 2017-07-19 |
RU2013158650A (ru) | 2015-07-20 |
MX2013014153A (es) | 2014-01-31 |
CN104975099A (zh) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003433A1 (es) | Método para analizar una muestra biológica de un sujeto con cáncer que comprende determinar un nivel de expresión de los biomarcadores gli-1, otx-2, shroom2, pdlim3, y sphk1 en dicha muestra, en donde el nivel de expresión de los biomarcadores en coparación con un control, proporciona un indicador de diagnóstico de si el sujeto tiene una probabilidad aumentada de respuesta a: un ácido metil-4’-trifluorometoxi-bifenil-3-carboxílixo [6-(cis-2,6-dimetil-morfolino-4-il)-piridin-3-il]-amida, ó 2-[(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2’] bipirizanil-5’-il]-propan-2-ol; método para seleccionar a un sujeto que tiene cáncer para el tratamiento con uno de dichos compuestos, el cual comprende determinar el nivel de expresión de shroom2 o sphk1, en una muestra biológica del sujeto. | |
EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
BR112014018970A8 (pt) | Dispositivos de coleta de amostra com agentes de estabilização sanguínea | |
SG10202010045QA (en) | Biosensors for biological or chemical analysis and methods of manufacturing the same | |
WO2014028378A3 (en) | Methods and systems for detecting biological components | |
MX364886B (es) | Lente oftálmica con sistema microfluídico. | |
NZ726748A (en) | A method of observing an auto fluorescence image of a cancer related substance through a fluorescence microscope | |
NZ713039A (en) | Water hardness monitoring via fluorescence | |
GB201113992D0 (en) | Device | |
EP3152582A4 (en) | Methods of detecting biological prints, fluids or analytes therein using porous semiconductor substrates | |
WO2014169011A3 (en) | Methods for treating immune diseases | |
SG11201607145VA (en) | Method for urine sample analysis, reagent for urine sample analysis, and reagent kit for urine sample analysis | |
SG11201607146RA (en) | Method for urine sample analysis, reagent for urine sample analysis, and reagent kit for urine sample analysis | |
WO2014153661A8 (en) | Method for detecting and monitoring bone loss | |
ES2521841B1 (es) | Procedimiento de diagnóstico y pronóstico de la enfermedad renal crónica en un sujeto humano | |
UA110670U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA109431U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA110964U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA113416U (uk) | СПОСІБ ПРОГНОЗУВАННЯ ПЕРЕБІГУ ПАНКРЕАТИТУ ЗА ПОЛІМОРФІЗМОМ ГЕНА TNF-α (G-308A) | |
UA109313U (uk) | Спосіб діагностики розвитку остеопорозу | |
TH157378A (th) | องค์ประกอบและวิธีการสำหรับการป้องกันและการรักษาการรั่วซึมของหลอดเลือดที่ถูกเหนี่ยวนำโดยมาสต์เซลล์ | |
UA111777U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA95657U (uk) | Спосіб прогнозування зрощення перелому | |
UA111850U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA111764U (uk) | Спосіб діагностики розвитку остеопорозу |